JO2634B1 - Compounds that have activity on the M1 receptor and their uses in medicines - Google Patents
Compounds that have activity on the M1 receptor and their uses in medicinesInfo
- Publication number
- JO2634B1 JO2634B1 JO2006342A JOP20060342A JO2634B1 JO 2634 B1 JO2634 B1 JO 2634B1 JO 2006342 A JO2006342 A JO 2006342A JO P20060342 A JOP20060342 A JO P20060342A JO 2634 B1 JO2634 B1 JO 2634B1
- Authority
- JO
- Jordan
- Prior art keywords
- fluorine atoms
- compounds
- substituted
- alkyl
- receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000017927 CHRM1 Human genes 0.000 title 1
- 101150073075 Chrm1 gene Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- -1 C1-6 aIkoxy Chemical group 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0519950.0A GB0519950D0 (en) | 2005-09-30 | 2005-09-30 | Compounds |
| GB0602040A GB0602040D0 (en) | 2006-02-01 | 2006-02-01 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO2634B1 true JO2634B1 (en) | 2012-06-17 |
Family
ID=37598231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JO2006342A JO2634B1 (en) | 2005-09-30 | 2006-09-28 | Compounds that have activity on the M1 receptor and their uses in medicines |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8283364B2 (enExample) |
| EP (1) | EP1943230B1 (enExample) |
| JP (1) | JP5209480B2 (enExample) |
| KR (2) | KR20130091791A (enExample) |
| CN (1) | CN101321736B (enExample) |
| AR (1) | AR056103A1 (enExample) |
| AT (1) | ATE492537T1 (enExample) |
| AU (1) | AU2006296369B2 (enExample) |
| BR (1) | BRPI0616609A2 (enExample) |
| CA (1) | CA2624504C (enExample) |
| CR (1) | CR9904A (enExample) |
| DE (1) | DE602006019119D1 (enExample) |
| EA (1) | EA016286B1 (enExample) |
| IL (1) | IL190219A (enExample) |
| JO (1) | JO2634B1 (enExample) |
| MA (1) | MA29849B1 (enExample) |
| MY (1) | MY148504A (enExample) |
| NO (1) | NO20081945L (enExample) |
| NZ (1) | NZ566508A (enExample) |
| PE (1) | PE20070490A1 (enExample) |
| TW (1) | TWI389905B (enExample) |
| UA (1) | UA101299C2 (enExample) |
| WO (1) | WO2007036715A2 (enExample) |
| ZA (1) | ZA200802167B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5209481B2 (ja) | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有する化合物および医薬におけるそれらの使用 |
| JP5209480B2 (ja) | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有する化合物および医薬におけるそれらの使用 |
| JP5209479B2 (ja) * | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有するベンゾイミダゾロン類 |
| US7766829B2 (en) * | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706165D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
| WO2009124882A1 (en) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists |
| GB0817982D0 (en) | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
| CA2966594A1 (en) * | 2014-11-03 | 2016-05-12 | William Beaumont Hospital | Method for treating underactive bladder syndrome |
| CA2984305C (en) * | 2015-04-29 | 2021-12-28 | Janssen Pharmaceutica Nv | Indolone compounds and their use as ampa receptor modulators |
| HUE053943T2 (hu) | 2015-04-29 | 2021-08-30 | Janssen Pharmaceutica Nv | Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk |
| US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| CN107673994A (zh) * | 2017-04-27 | 2018-02-09 | 联化科技股份有限公司 | 一种芳基甲烷类化合物的制备方法 |
| CN107739342B (zh) * | 2017-11-29 | 2020-01-10 | 华南理工大学 | 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法 |
| CN117049938B (zh) * | 2023-06-20 | 2024-06-14 | 山东轩德医药科技有限公司 | 一种6-溴-2,3-二氟甲苯的制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3161645A (en) * | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
| US3989707A (en) * | 1974-06-21 | 1976-11-02 | Janssen Pharmaceutica N.V. | Benzimidazolinone derivatives |
| US4292321A (en) * | 1979-05-24 | 1981-09-29 | Warner-Lambert Company | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof |
| DE3124366A1 (de) * | 1981-06-20 | 1982-12-30 | Hoechst Ag, 6000 Frankfurt | N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung |
| DE4040300A1 (de) | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
| JP3916093B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | 光学活性イミダゾリジノン誘導体とその製造方法 |
| JP2002515008A (ja) * | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ムスカリン・アンタゴニスト |
| US5574044A (en) * | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
| US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
| WO1997016186A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine agonists |
| US5718912A (en) * | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6465484B1 (en) * | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO1999032481A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| EP1263754A1 (en) * | 2000-02-01 | 2002-12-11 | Millennium Pharmaceuticals, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
| ES2340441T3 (es) * | 2001-04-18 | 2010-06-02 | Euro-Celtique S.A. | Compuestos de octahidrobencimidazolona como analgesicos. |
| CA2444595A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| US6951849B2 (en) * | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| KR20040047877A (ko) * | 2001-10-02 | 2004-06-05 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 제제로서 벤즈이미다졸리디논 유도체 |
| EP1451173A4 (en) * | 2001-11-01 | 2005-10-26 | Icagen Inc | PIPERIDINE |
| ES2392340T3 (es) | 2002-03-29 | 2012-12-07 | Mitsubishi Tanabe Pharma Corporation | Remedio para los trastornos del sueño |
| AU2003245565B2 (en) | 2002-06-17 | 2008-01-03 | Banyu Pharmaceutical Co., Ltd. | Ophthalmic compositions for treating ocular hypertension |
| CA2509711A1 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Piperidine derivatives as ccr5 antagonists |
| JP2005102133A (ja) | 2003-04-28 | 2005-04-14 | Ricoh Co Ltd | 画像形成装置及び宛先情報参照方法 |
| JP2006528186A (ja) * | 2003-07-23 | 2006-12-14 | ワイス | 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニルジヒドロベンゾイミダゾロン化合物 |
| GEP20084527B (en) * | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
| EP1809607B1 (en) * | 2004-11-02 | 2008-12-17 | Pfizer, Inc. | Sulfonyl benzimidazole derivatives |
| US7300947B2 (en) * | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| JP5209479B2 (ja) | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有するベンゾイミダゾロン類 |
| JP5209480B2 (ja) | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有する化合物および医薬におけるそれらの使用 |
| JP5209481B2 (ja) | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有する化合物および医薬におけるそれらの使用 |
| BRPI0716602A2 (pt) | 2006-09-08 | 2013-09-17 | Gillette Co | escova de dentes com méltiplos estados de cerda |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706187D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706189D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706165D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706188D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706190D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706170D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706167D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706173D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-09-27 JP JP2008532866A patent/JP5209480B2/ja not_active Expired - Fee Related
- 2006-09-27 NZ NZ566508A patent/NZ566508A/en not_active IP Right Cessation
- 2006-09-27 CN CN2006800451692A patent/CN101321736B/zh not_active Expired - Fee Related
- 2006-09-27 UA UAA200803937A patent/UA101299C2/uk unknown
- 2006-09-27 AU AU2006296369A patent/AU2006296369B2/en not_active Ceased
- 2006-09-27 WO PCT/GB2006/003590 patent/WO2007036715A2/en not_active Ceased
- 2006-09-27 EA EA200801001A patent/EA016286B1/ru not_active IP Right Cessation
- 2006-09-27 AT AT06794584T patent/ATE492537T1/de not_active IP Right Cessation
- 2006-09-27 MY MYPI20080901A patent/MY148504A/en unknown
- 2006-09-27 EP EP06794584A patent/EP1943230B1/en active Active
- 2006-09-27 KR KR1020137020049A patent/KR20130091791A/ko not_active Ceased
- 2006-09-27 KR KR1020087007797A patent/KR101374458B1/ko not_active Expired - Fee Related
- 2006-09-27 US US12/088,465 patent/US8283364B2/en not_active Expired - Fee Related
- 2006-09-27 CA CA2624504A patent/CA2624504C/en not_active Expired - Fee Related
- 2006-09-27 DE DE602006019119T patent/DE602006019119D1/de active Active
- 2006-09-27 BR BRPI0616609-1A patent/BRPI0616609A2/pt not_active IP Right Cessation
- 2006-09-28 TW TW095135887A patent/TWI389905B/zh not_active IP Right Cessation
- 2006-09-28 PE PE2006001183A patent/PE20070490A1/es not_active Application Discontinuation
- 2006-09-28 JO JO2006342A patent/JO2634B1/en active
- 2006-09-28 AR ARP060104268A patent/AR056103A1/es unknown
-
2007
- 2007-09-10 US US11/852,455 patent/US8481566B2/en not_active Expired - Fee Related
-
2008
- 2008-03-17 IL IL190219A patent/IL190219A/en not_active IP Right Cessation
- 2008-04-04 MA MA30812A patent/MA29849B1/fr unknown
- 2008-04-18 CR CR9904A patent/CR9904A/es unknown
- 2008-04-23 NO NO20081945A patent/NO20081945L/no not_active Application Discontinuation
-
2009
- 2009-03-07 ZA ZA200802167A patent/ZA200802167B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2634B1 (en) | Compounds that have activity on the M1 receptor and their uses in medicines | |
| NO20084048L (no) | Benzimidazoler som har aktivitet ved M1 receptor og deres anvendelser i medisin | |
| NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| PH12013501754A1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| NZ613219A (en) | Heterocyclic containing entities, compositions and methods | |
| TN2012000071A1 (en) | Heterocyclic compounds and uses thereof | |
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| MX2012008049A (es) | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| NZ706506A (en) | Heterocyclic compounds and uses thereof | |
| TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
| MX339823B (es) | Ingenol-3-acilatos iii e ingenol-3-carbamatos. | |
| UA86602C2 (ru) | Применение соединений антагониста crth2 в терапии | |
| IL202617A0 (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
| NO20080445L (no) | Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer | |
| WO2007036718A3 (en) | Compounds which have activity at m1 receptor and their uses in medicine | |
| ATE450514T1 (de) | Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung | |
| EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| TW200704640A (en) | Pyrazolecarboxamides | |
| WO2014060852A3 (en) | Compounds useful in the synthesis of benzamide compounds | |
| UA101162C2 (ru) | Производные индол-2-она, двузамещенные в положении 3, их получение и применение в терапии | |
| EA201101207A1 (ru) | Применение антагонистов рецептора nk | |
| UA114017C2 (xx) | Похідні аміноциклобутану, спосіб їх одержання та їх застосування як лікарських засобів |